Apimeds Pharmaceuticals US, Inc.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$6.0M
- Total assets
- $164.2M
- Market cap
- $19.2M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $11.9M
- Operating income
- -$11.9M
- Net income
- -$6.0M
- EPS (basic)
- $-0.55
- EPS (diluted)
- $-0.55
Balance sheet
- Total assets
- $164.2M
- Current assets
- $14.0M
- Total liabilities
- $10.8M
- Current liabilities
- $10.7M
- Shareholders’ equity
- $153.3M
Cash flow
- Operating cash flow
- -$8.9M
- Investing cash flow
- -$10.1M
- Financing cash flow
- $20.6M
- Net cash flow
- $1.6M
Statements via Polygon.io (SEC filings)
- Market cap
- $19.2M
- EPS (diluted)
- $-0.55
- Shares outstanding
- 15.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 9, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $6.0M.
- Trading 97% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Apimeds Pharmaceuticals US, Inc..
Write a review
News about Apimeds Pharmaceuticals US, Inc.
News & sentiment via Polygon.io
